Latest App Notes & Case Studies

In quantifying therapeutic peptides and proteins in biological matrices, traditional ELISA-only based techniques can suffer from high variability, narrow dynamic range, problems with selectivity and typically cannot use internal standards.

Sample preparation and alternative chromatography techniques are often used to meet the sensitivity needs required in routine bioanalytical assays, but these methods can be time consuming.

In biotherapeutic development, decreased drug doses and limited sample volumes require higher quantification sensitivity, while the complexity of biological matrices calls for the need of assay selectivity improvement.

Demands for improved sensitivity in routine bioanalytical assays continue to increase as drug discovery and development programs focus on more efficacious, lower dosage compounds. Pharma development scientists supporting this work therefore require highly sensitive and selective bioanalytical methods for quantification.

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

One approach to develop drugs for infectious diseases involves a comprehensive understanding of human-pathogen protein interactions, as targeting host proteins helps reduce the possibility of drug resistance by creating a more significant evolutionary barrier for the virus.

Download this application focus to learn more about the benefits of automated sample preparation for drug development.

A Customized XF Workflow for Detection and Characterization of Mitochondrial Toxicity

Many different classes of drugs can cause drug-induced mitochondrial toxicity, which may result in brain, cardiac, liver, muscle and/or kidney injury.

Surface plasmon resonance (SPR) is a core technology used in many pharma and biotechnology settings for this purpose, however traditional initial SPR screening of weak affinity compounds using a single fixed concentration injection can present numerous challenges.

Comprehensive disease modeling can be challenging for many labs due to variations in reagents, cell culture conditions, technical inconsistencies across protocols and experiments and bandwidth limitations.